Effect of clomiphene citrate for prevention of premature LH surge in Intra uterine Insemanation cycles.

Effect of clomiphen citrate in pcos patients underging Intra uterine Insemanation cycles.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016022010210N4

Enrollment

162

Registered

2016-06-15

Start date

2012-07-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effect of clomiphene citrate in prevention of premature LH surge in PCOS patients underging IUI. Female infertility associated with anovulation

Interventions

Intervention 1: In clomiphene citrate group recombinant FSH (Gonal –F ,serono) 75 IU /day from 2nd day of cycle till the day of HCG injection and clomiphene citrate 150 mg/day (REZA K –Tehran) from th

Treatment - Drugs

In clomiphene citrate group recombinant FSH (Gonal –F ,serono) 75 IU /day from 2nd day of cycle till the day of HCG injection and clomiphene citrate 150 mg/day (REZA K –Tehran) from the 8th to the day

In the control group only recombinant FSH (Gonal –F ,serono) 75 IU /day from 2nd day of cycle till the day of HCG injection was prescribed.

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients who have 2 or more of including factors for ESHRE criteria for polycystic ovary synrdrome and have history of at least one year infertility and 3 cycles clomiphene citrate resistance?Diagnosis criteria for PCOs according to ESHRE-ASRM(ESHRE/ASRM criteria for PCOS:chronic anovulation ,clinical or biochemical evidence of androgen excess and polycystic appearing ovaries on trans vaginal sonography ) Exclusion criteria : Collateral effect such as probability of no response to the treatment? OHSS gonadotropin syndrome? lake of patient collaboration in performing drug cycle

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Premature LH surge. Timepoint: On the day of HCG injection. Method of measurement: measurement of serum LH level of laboratory.;Number of nature follicles. Timepoint: on the day of HCG injection. Method of measurement: measurement of number of mature follicles by trans vaginal sonography (TVS).;Amount of serum esteradiol( E2) level. Timepoint: On the day of HCG injection. Method of measurement: Measurement of serum E2 level in lab.;Endometrial thickness. Timepoint: on the day of HCG injection. Method of measurement: measurement of endometrial thickness by trans vaginal sonography (TVS).	—

Measure

Time frame

Premature LH surge. Timepoint: On the day of HCG injection. Method of measurement: measurement of serum LH level of laboratory.;Number of nature follicles. Timepoint: on the day of HCG injection. Method of measurement: measurement of number of mature follicles by trans vaginal sonography (TVS).;Amount of serum esteradiol( E2) level. Timepoint: On the day of HCG injection. Method of measurement: Measurement of serum E2 level in lab.;Endometrial thickness. Timepoint: on the day of HCG injection. Method of measurement: measurement of endometrial thickness by trans vaginal sonography (TVS).

—

Secondary

Measure	Time frame
Chemical or clinical pregnancy. Timepoint: One week after retard of menstrual time ,at the 6th -7th week of gestation. Method of measurement: trans vaginal sonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahshid Alborzi

Shiraz University of Medical Sciences

alborzimah@gmail .com+98 71 3227 9715

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026